GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Interest and Commission Paid

KYTX (Kyverna Therapeutics) Interest and Commission Paid


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Interest and Commission Paid?

Interest and Commission Paid only applicable to companies reporting Cash Flow from Operations in direct method.


Kyverna Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.